< Previous1031st ECCMID ONLINE – INDUSTRY GUIDE Integrated Symposia Overview Friday, 9 July 2021 Integrated Session 1Integrated Session 2Integrated Session 3Integrated Session 4Integrated Session 5 13:15 - 15:1513:15 - 14:1513:15 - 15:1513:15 - 15:15 2692 Revising the paradigm: the importance of adult vaccination against respiratory diseases Pfizer/BioNTech 2788 The challenges of managing the COVID-19 pandemic from pre- analytic to diagnosis Copan 2789 Viruses mutate, and SARS-CoV-2 is no exception. Emerging mutation surveillance and confirmation Thermo Fisher 3220 Spotlight on COVID-19: where are we now? Janssen Pharmaceuticals 14:15 - 15:15 2795 Developing new vaccines to protect against infectious diseases at home and abroad Valneva 15:15 - 16:15 2797 How the pandemic changed the pathway of diagnosis of infectious diseases: rapid diagnostic solutions for COVID-19 Abbott 16:15 - 18:1516:15 - 18:1516:15 - 18:1516:15 - 17:45 2762 Importance of influenza vaccination in the COVID-19 environment SanofiPasteur 2711 Superbugs, Susceptibility & Stewardship: with more antibiotics available for multidrug-resistant Gram-negative bacterial infections, what’s holding us back? Menarini 2694 Deciphering the data: clinical impact of vaccines and monoclonal antibodies for COVID-19 AstraZeneca 2696 The role of patients in infectious disease research: from study participants to scientific partners Pfizer1131st ECCMID ONLINE – INDUSTRY GUIDE Integrated Symposia Overview Saturday, 10 July 2021 Integrated Session 1Integrated Session 2Integrated Session 3Integrated Session 4 08:30 - 09:3008:30 - 10:0008:30 - 10:30 2695 An innovative approach to infection control Seegene Inc. 2763 Surviving invasive meningococcal disease (IMD): the long-term impact and future preventive perspectives SanofiPasteur 2697 Gram-negative infections in the post-COVID world: what are we left with? Merck Sharp & Dohme 09:00 - 10:30 2698 Novel rapid diagnostic solutions aiming to improve the diagnosis of C. difficile infections and respiratory infections Quidel Ireland Ltd. 13:15 - 14:4513:15 - 15:1513:15 - 15:1513:15 - 14:15 2702 Adult pneumococcal vaccination: evidence to inform optimal policy for at-risk groups and the role of polysaccharide vaccines Merck Sharp & Dohme 2700 Taking a look inside the Trojan Horse Shionogi & Co., Ltd. 2701 Are we ready for personalised medicine in the treatment of mould infections? F2G Ltd. 4162 COVID-19: out of adversity comes learnings Pfizer 16:15 - 18:1516:15 - 18:1516:15 - 17:4516:15 - 17:15 2704 Changing microbiology: enhancing technologies to address today’s critical diseases Bruker Daltonics GmbH & Co. KG 2705 Piecing together the patient puzzle: navigating the MDR Gram-negative infection treatment paradigm Pfizer 2713 The role and timing of antiviral therapy in the treatment of COVID-19 Gilead Europe Sciences Ltd. 2708 Syndromic testing, a new standard of care bioMérieux S.A1231st ECCMID ONLINE – INDUSTRY GUIDE Integrated Symposia Overview Sunday, 11 July 2021 Integrated Session 1Integrated Session 2Integrated Session 3Integrated Session 4Integrated Session 5 08:30 - 10:3008:30 - 10:30 2693 Easing patient management and improving patient outcomes with innovative molecules Menarini 2710 Changing the paradigm of COVID-19 management: early diagnosis and treatment in non- hospitalised patients Merck Sharp & Dohme 09:30 - 10:30 2790 NTM Pulmonary Disease: do we need to rethink our manage- ment strategies? Insmed 13:15 - 14:1513:15 - 15:1513:15 - 15:1513:15 - 15:15 2712 Latest advances in diagnostic and treatment solutions for the COVID-19 pandemic: overcoming challenges in a rapidly evolving environment F.Hoffmann-La Roche 2706 New frontiers in inva- sive fungal diseases Gilead Europe Sciences Ltd. 2715 Treating invasive mould disease in an era of complex epidemiology and patient needs Pfizer 2703 Place in therapy of contemporary lipoglycopeptides and cephalosporins in an evolving environment needs Advanz Pharma 16:15 - 18:1516:15 - 18:1516:15 - 18:1516:15 - 17:1516:15 - 18:15 2796 Diagnosis and immune response of SARS- CoV-2 infection DiaSorin 2717 What are the treatment options for CAP and cSSTI in 2021? Pfizer 2718 The clinical microbiology lab in 2021: resistance detection and more Beckman Coulter 3207 Monoclonal antibodies (mAbs) in the treatment of COVID-19: what have we learnt? GSK 2791 Bacteraemia diagnostics in a brave new viral world: clinical microbiology and patient management considerations Accelerate Diagnostics Inc. 17:15 - 18:15 3162 AMR and the need for innovation: where we are now? And where do we need to be? GSK 1331st ECCMID ONLINE – INDUSTRY GUIDE Integrated Symposia Overview Monday, 12 July 2021 Integrated Session 1Integrated Session 2Integrated Session 3Integrated Session 4 09:30 - 10:30 2792 The crucial role of rapid diagnostics in the early detection of secondary bacterial and fungal infections complicating COVID-19 T2 Biosystems 13:15 - 15:15 2699 Syndromic diagnostics: better timing and better insights to improve patient care in COVID-19 and beyond Qiagen 16:15 - 18:15 2707 Enabling critical testing needs in clinical microbiology: innovative, random-access molecular diagnostic solutions to address pandemic and post-pandemic needs Qiagen1431st ECCMID ONLINE – INDUSTRY GUIDE Integrated Symposia 2692 13:15 - 15:15 13. Integrated sessions - 1 2-hour Integrated Symposium Revising the paradigm: the importance of adult vaccination against respiratory diseases Chair: Ralf Rene Reinert (Paris, France) ESCMID-appointed chair Marc J.M. Bonten (Utrecht, Netherlands) 2692-1 13:15 Opening remarks by the Chairs 2692-2 13:30 Pneumococcal conjugate vaccination for adults: need for expanded valent conjugate vaccine Peter Paradiso (Newton Square, United States) 2692-3 13:45 Assessing the burden of pneumococcal pneumonia in adults Antoni Torres (Barcelona, Spain) 2692-4 14:00 Pneumococcal panel discussion Marc J.M. Bonten (Utrecht, Netherlands) Peter Paradiso (Newtown Square, United States) Ralf Rene Reinert (Paris, France) Antoni Torres (Barcelona, Spain) 2692-5 14:20 mRNA vaccines: the accelerated development of a COVID-19 vaccine including clinical development and early data on effectiveness Özlem Türeci (Mainz, Germany) 2692-6 15:00 Q&A Ralf Rene Reinert (Paris, France) Marc J.M. Bonten (Utrecht, Netherlands) Özlem Türeci (Mainz, Germany) 2692-7 15:10 Closing remarks by the Chairs Organised by Pfizer/BioNTech Friday, 9 July 20211531st ECCMID ONLINE – INDUSTRY GUIDE Friday, 9 July 2021 2788 13:15 - 14:15 14. Integrated Sessions – 2 1-hour Integrated Symposium The challenges of managing the COVID-19 pandemic from pre-analytic to diagnosis Chair David Hawkes (Carlton, Australia) ESCMID-appointed chair Jordi Vila Estape (Barcelona, Spain) 2788-1 13:15 The challenges of managing the COVID-19 pandemic from pre-analytic to diagnosis Paolo Gaibani (Bologna, Italy) 2788-2 13:55 Discussion and Q&A Organised by Copan1631st ECCMID ONLINE – INDUSTRY GUIDE Friday, 9 July 2021 2789 13:15 - 15:15 15. Integrated Sessions – 3 2-hour Integrated Symposium Viruses mutate, and SARS-CoV-2 is no exception. Emerging mutation surveillance and confirmation Chair Simone Vanoni (Niederalm, Austria) ESCMID-appointed chair Mary Horgan (Cork, Ireland) 2789-1 13:15 Welcome and introduction by the Chairs 2789-2 13:30 Performance characteristics of COVID-19 tests: a comparative study Ulrich Eigner (Heidelberg, Germany) 2789-3 13:50 SARS-CoV-2 testing in the community: finding variants in real-time Alan McNally (Birmingham, United Kingdom) 2789-4 14:05 Designed with virus mutations in mind: SARS-CoV-2 testing and sequencing solutions Jelena Feenstra (Vienna, Austria) 2789-5 14:25 SARS-CoV-2 testing and sequencing for international arrivals reveals significant cross border transmission of high risk variants into the United Kingdom Marco Loddo (Cambridge, United Kingdom) 2789-6 14:40 Regional rapid surveillance of SARS-CoV-2 infection Marcel Jonges (Amsterdam, Netherlands) 2789-7 14:55 Panel discussion, Q&A and closing remarks Organised by Thermo Fisher1731st ECCMID ONLINE – INDUSTRY GUIDE Friday, 9 July 2021 3220 13:15 - 15:15 17. Integrated Sessions – 5 2-hour Integrated Symposium Spotlight on COVID-19: where are we now? Chair Antonella Castagna (Civate, Italy) ESCMID-appointed chair Nicola Petrosillo (Rome, Italy) 3220-1 13:15 Welcome and introduction by the Chairs 3220-2 13:25 COVID-19: where we are now? TBD 3220-3 13:45 COVID-19: long-term clinical challenges from the pandemic’s frontline Michael Marks (London, United Kingdom) 3220-4 14:05 Methods of COVID-19 prevention: an overview Andrew Ustianowski (Manchester, United Kingdom) 3220-5 14:25 Vaccination and COVID-19 prevention Glenda Gray (Witwatersrand, South Africa) 3220-6 14:45 Panel discussion and Q&A 3220-7 15:10 Closing remarks by the Chairs Organised by Janssen Pharmaceuticals1831st ECCMID ONLINE – INDUSTRY GUIDE Friday, 9 July 2021 2795 14:15 - 15:15 16. Integrated Sessions – 4 1-hour Integrated Symposium Developing new vaccines to protect against infectious diseases at home and abroad Chair Katrin Dubischar (Vienna, Austria) ESCMID-appointed chair Thea Kølsen Fischer (Hillerød, Denmark) 2795-1 14:15 The portfolio approach: lessons learned from the UK vaccine task forces response to COVID-19 Adam Finn (Bristol, United Kingdom) 2795-2 14:25 Interactive questions 2795-3 14:30 Travel and the pandemic: challenges faced by specialist travel clinics and how travel changed Tomas Jelinek (Berlin, Germany) 2795-4 14:40 Interactive questions 2795-5 14:45 Leveraging established technologies: an inactivated vaccine candidate (VLA2001) with a novel adjuvant combination to protect against COVID-19 Adam Finn (Bristol, United Kingdom) 2795-6 14:55 Interactive questions 2795-7 15:00 Emerging Infectious Disease: Chikungunya as a public health threat and introduction to a novel vaccine candidate (VLA1553) Tomas Jelinek (Berlin, Germany) 2795-8 15:10 Interactive questions Organised by Valneva1931st ECCMID ONLINE – INDUSTRY GUIDE Friday, 9 July 2021 2797 15:15 - 16:15 13. Integrated sessions - 1 1-hour Integrated Symposium How the pandemic changed the pathway of diagnosis of infectious diseases: rapid diagnostic solutions for COVID-19 Chair Henri Bendelac (Craponne, France) ESCMID-appointed chair Veroniek Saegeman (Sit-Niklaas, Belgium) 2797-1 15:15 Welcome and introduction by the Chairs 2797-2 15:18 Point of Care tests to the rescue, again Mohammed Mansoor Raza (Milton Keynes, United Kingdom) 2797-3 15:32 Impact of a very fast molecular testing of SARS-CoV-2 in emergency departments Jerome Le Goff (Paris, France) 2797-4 15:46 Can rapid tests support public health interventions? Claudia Denkinger (Heidelberg, Germany) 2797-5 16:00 Panel discussion and Q&A Organised by AbbottNext >